NEONATAL HYPERBILIRUBINEMIA
1133
[21] American Academy of Pediatrics Subcommittee on Hyperbilirubinemia. Management of hyperbilirubinemia in the new born infant 35 or more weeks of gestation. Pediatrics 2004; 114:297–316. [22] Porter LM, Dennis BL. Hyperbilirubinemia in the term newborn. Am Fam Physician 2002; 65(4):599–605. [23] Kaplan M, Hammerman C. Understanding and preventing severe neonatal hyperbilirubinemia: is bilirubin neurotoxity really a concern in the developed world. Clin Perinatol 2004; 31(3):555–75. [24] Khoury MJ, Calle EE, Joesoef RM. Recurrence risk of neonatal hyperbilirubinemia in siblings. Am J Dis Child 1988;142(10):1065–9. [25] Knudsen A, Ebbesen F. Cephalocaudal progression of jaundice in newborns admitted to neonatal intensive care units. Biol Neonate 1997;71:357–61. [26] Bhutani VK, Gourley GR, Adler S, et al. Noninvasive measurement of total serum bilirubin in a multiracial predischarge newborn population to assess the risk of severe hyperbilirubinemia. Pediatrics 2000;106(2):e17. [27] Davidson LT, Merritt KK, Weech AA. Hyperbilirubinemia in the newborn. Am J Dis Child 1941;61:958–80. [28] Moyer VA, Ahn C, Sneed S. Accuracy of clinical judgment in neonatal jaundice. Arch Pediatr Adolesc Med 2000;154:391–4. [29] Tenovuo A. Neonatal complications in small-for-gestational age neonates. J Perinat Med 1988;16:197–201. [30] Keren R, Bhutani VK, Luan X, et al. Identifying newborns at risk of significant hyperbilirubinemia: a comparison of two recommended approaches. Arch Dis Child 2005;90: 415–21. [31] Thacker KE, Lim T, Drew JH. Cephalhematoma: a 10 year review. Aust N Z J Obstet Gynecol 1987;27(3):210–2. [32] Perlow JH, Wigton T, Hart J, et al. Birth trauma: a five-year review of incidence and associated perinatal factors. J Reprod Med 1996;41(10):754–60. [33] Davies DP, Gomersall R, Robertson R, et al. Neonatal jaundice and maternal oxytocin infusion. Br Med J 1973;3:476–7. [34] Chung MA. Galactosemia in infancy: diagnosis, management, and prognosis. Pediatr Nurs 1997;23(6):563–8. [35] Maisels M. Neonatal jaundice. Pediatr Rev 2006;27(12):443–54. [36] Waldron P, De Alarcon P. ABO hemolytic disease of the newborn: a unique constellation of findings in siblings and review of protective mechanisms in the fetal-maternal system. Am J Perinatol 1999;16(8):391–8. [37] Zawodnik SA, Bonnard GD, Gautier E. Antibody-dependent cell-mediated destruction of human erythrocytes sensitized in ABO and rhesus fetal-maternal incompatibilities. Pediatr Res 1976;10:791–6. [38] Kaplan M, Hammerman C. Severe neonatal hyperbilirubinemia: a potential complication of glucose-6-phosphate dehydrogenase deficiency. Clin Perinatol 1998;25(3):575–90. [39] Iranpour R, Akbar MR, Haghshenas I. Glucose-6-phosphate dehydrogenase deficiency in neonates. Indian J Pediatr 2003;70(11):855–7. [40] Huang MJ, Kua KE, Teng HC, et al. Risk factors for severe hyperbilirubinemia in neonates. Pediatr Res 2004;56(5):682–9. [41] Atay E, Bozaykut A, Ipek IO. Glucose-6-phosphate dehydrogenase deficiency in neonatal indirect hyperbilirubinemia. J Trop Pediatr 2006;52(1):56–8. [42] Hammer SG, Lewan RB. Neonatal hyperbilirubinemia caused by pyruvate kinase deficiency. J Am Board Fam Med 1988;1(4):288–90. [43] Kedar PS, Warang P, Colah RB, et al. Red cell pyruvate kinase deficiency in neonatal jaundice cases in India. Indian J Pediatr 2006;73(11):985–8. [44] Trucco JI, Brown AK. Neonatal manifestations of hereditary spherocytosis. Am J Dis Child 1967;113:263–70.